Business
Further Clinical Evidence
Further Clinical Evidence.
About this update from Advanced Medical Solutions Group Plc
[{"type":"text","content":"\n \nRNS Number : 0969K Advanced Medical Solutions Grp PLC 11 July 2011 \n \n\nFor Release: 11 July 2011\n \n \n \nAdvanced Medical Solutions Group plc\n(\"AMS\")\n \nFurther Evidence in Support of AMS Antimicrobial Products\n \nAdvanced woundcare dressing effective against 160 different types of\nChronic and Burn Wound Microorganisms, including 29 strains of MRSA \n \nWinsford, UK: Advanced Medical Solutions Group plc (AIM: AMS.L), the global medical technology company, today announces that, as part of the continued support to its global business partners, two further clinical studies have recently been published, targeted to help drive continued growth in AMS's key silver alginate woundcare business.\n \nThe studies, which were published in both The International Wound Journal and the Journal of Woundcare, demonstrate the antimicrobial efficacy of one of AMS's commercialised silver alginate dressings in killing 160 chronic and burn wound microorganisms, including 29 strains of the superbug Methicillin-resistant Staphylococcus Aureus (MRSA).\n \nCommenting on this announcement, Chris Meredith, Chief Executive Officer of AMS stated: \n \n\"We are very pleased with the efficacy results for our silver alginate woundcare products, which continue to prove effective against MRSA, one of the most problematic infections to treat. Our quality silver alginate products, coupled with supporting clinical evidence such as these latest studies, have helped our partners successfully capture 20% of the US$230 million global antimicrobial fibre market in the last five years. We look forward to continued success in this area.\"\n \n- ends -\n \n\n\n\n\nFor further enquiries:\n \n\n\n \n\n\n\n\nAdvanced Medical Solutions Group plc\nChris Meredith, Chief Executive Officer\nMary Tavener, Finance Director\n \n\n\n+44 (0) 1606 545508\n\n\n\n\nTavistock Communications\nJohn West / Chris Munden / Andrew Dunn\n \n\n\n+44 (0) 20 7920 3150\n\n\n\n\n \nNotes to Editors:\n \nAMS' advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They p...